<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04384198</url>
  </required_header>
  <id_info>
    <org_study_id>EA4/193/19</org_study_id>
    <nct_id>NCT04384198</nct_id>
  </id_info>
  <brief_title>TransCranial Doppler for REDUCtion of Silent strokE During MitraClip Implantation</brief_title>
  <acronym>TCD-REDUCE</acronym>
  <official_title>TransCranial Doppler for REDUCtion of Silent strokE During MitraClip Implantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Berlin Institute of Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary goal of the TCD-REDUCE study is to demonstrate the effectiveness of continuous
      transcranial Doppler sonography (&quot;sonolysis&quot;) on the reduction of the ischemic stroke volume
      during MitraClip implantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cardiac procedures are associated with new cerebral ischemic lesions detected on
      diffusion-weighted MRI (Bendszus et al., 2006).

      A previous study suggests that sonolysis (continuous transcranial Doppler sonography using a
      2-MHz diagnostic probe) can reduce the risk of new cerebral ischemic lesions during carotid
      endarterectomy and carotid angioplasty / stenting (Skoloudik et al., 2015).

      Currently, it is unknown whether sonolysis can also reduce the risk of new cerebral ischemic
      lesions during MitraClip implantation - a percutaneous treatment option in patients with
      moderate / severe mitral regurgitation.

      In this study, patients will receive cerebral MRI and clinical neurological /
      neuropsychological examination before and after MitraClip implantation. During MitraClip
      implantation, all patients will receive continuous transcranial Doppler sonography using a
      2-MHz diagnostic probe with maximal diagnostic energy administered through either the left or
      the right transtemporal window (computer-generated 1:1 randomization).

      The primary endpoint is the median ischemic lesion volume detected on diffusion-weighted MRI
      after MitraClip implantation in the sonolysis group and in the control group.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2020</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>PROBE</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>stroke volume</measure>
    <time_frame>0-5 days after the MitraClip Implantation</time_frame>
    <description>median volume (in ml) of new ischemic lesions detected on diffusion-weighted MRI after MitraClip implantation in the sonolysis and in the control group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>diffusion-weighted MRI lesions</measure>
    <time_frame>0-5 days after the MitraClip Implantation</time_frame>
    <description>new ischemic lesions (occurrence, number and location) detected on diffusion-weighted MRI after MitraClip implantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>intracerebral hemorrhage (ICH) and / or subarachnoid hemorrhage (SAH)</measure>
    <time_frame>0-5 days after the MitraClip Implantation</time_frame>
    <description>new ICH and / or SAH detected on T2*-weighted MRI after MitraClip implantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cerebral microbleeds (CMB)</measure>
    <time_frame>0-5 days after the MitraClip Implantation</time_frame>
    <description>new cerebral microbleeds detected on T2*-weighted MRI after MitraClip implantation (occurrence, number and location)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinically overt stroke</measure>
    <time_frame>(1) 0-5 days after the MitraClip Implantation and (2) 3 months after MitraClip implantation</time_frame>
    <description>new clinically overt stroke (ischemic or hemorrhagic) or transient ischemic attack (TIA) after MitraClip implantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>functional outcome</measure>
    <time_frame>(1) 0-5 days after the MitraClip Implantation and (2) 3 months after MitraClip implantation</time_frame>
    <description>functional outcome will be evaluated using the modified Rankin scale (mRS). The mRS ranges from 0 to 6 with 0 indicating no functional deficit (best score) and 6 indicating deaths (worst score).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cognitive outcome during hospital stay</measure>
    <time_frame>0-5 days after the MitraClip Implantation</time_frame>
    <description>cognitive outcome will be evaluated using the Montreal Cognitive Assessment (MoCA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cognitive outcome at follow-up</measure>
    <time_frame>3 months after MitraClip implantation</time_frame>
    <description>cognitive outcome will be evaluated using the Telephone Interview for Cognitive Status (TICS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>delirium</measure>
    <time_frame>0-5 days after the MitraClip Implantation</time_frame>
    <description>delirium will be evaluated using the 3-Minute Diagnostic Interview for Confusion Assessment Method (3D-CAM)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>length of hospital stay (duration of hospitalization for the MitraClip implantation)</measure>
    <time_frame>length of hospital stay (up to 3 months after MitraClip implantation)</time_frame>
    <description>days of hospital stay from admission to hospital to discharge from hospital including direction of discharge (home, another hospital)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality</measure>
    <time_frame>up to 3 months after MitraClip implantation</time_frame>
    <description>mortality</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Mitral Valve Insufficiency</condition>
  <arm_group>
    <arm_group_label>Sonolysis group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cerebral hemisphere with sonolysis during MitraClip implantation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Cerebral hemisphere without sonolysis during MitraClip implantation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sonolysis</intervention_name>
    <description>Continuous transcranial Doppler sonography (TCD) using a 2-MHz diagnostic probe with maximal diagnostic energy</description>
    <arm_group_label>Sonolysis group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients with mitral regurgitation that are assigned to the MitraClip implantation by an
        interdisciplinary heart team according to current guidelines.

        Exclusion Criteria:

          -  contraindication to MRI examination (e.g. pace-maker, implanted metal material,
             claustrophobia)

          -  pregnancy

          -  unable to consent

          -  no transtemporal window
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian H Nolte, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite University, Berlin, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tim Bastian Braemswig, MD</last_name>
    <phone>+49 30 450560624</phone>
    <email>tim-bastian.braemswig@charite.de</email>
  </overall_contact>
  <reference>
    <citation>Školoudík D, Kuliha M, Hrbáč T, Jonszta T, Herzig R; SONOBUSTER Trial Group. Sonolysis in Prevention of Brain Infarction During Carotid Endarterectomy and Stenting (SONOBUSTER): a randomized, controlled trial. Eur Heart J. 2016 Oct 21;37(40):3096-3102. Epub 2015 Sep 28.</citation>
    <PMID>26417059</PMID>
  </reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 30, 2020</study_first_submitted>
  <study_first_submitted_qc>May 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2020</study_first_posted>
  <last_update_submitted>May 11, 2020</last_update_submitted>
  <last_update_submitted_qc>May 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Christian Nolte</investigator_full_name>
    <investigator_title>Prof. Dr. Christian H. Nolte</investigator_title>
  </responsible_party>
  <keyword>MitraClip</keyword>
  <keyword>Sonolysis</keyword>
  <keyword>Stroke</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

